Masimo Corp

Masimo Corp(MASI)股票分析

$179.950

+0.018 (+0.01%)收盘时

Loading chart…
最高
179.990
开盘
179.950
成交量加权均价
179.96
成交量
3.16M
市值
6.99B
最低
179.950
成交额
568.70M
企业价值/息税折旧摊销前利润(TTM)
21.69

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

AI 分析 of Masimo Corp (MASI)

卖出

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

分析师评级(6)

上行空间 +4.70%
买入
3 买入
3 持有
0 卖出
当前: 179.95
最低
162.00
平均
188.40
最高
210.00

Raymond James

2026-03-27

目标价

$180

Market Perform

Wells Fargo

2026-03-18

目标价

$180

Equal Weight

Wells Fargo

2025-12-05

目标价

$190

增持

BTIG

2025-12-04

目标价

$200

买入

BofA

2025-11-17

目标价

$162

中性

估值指标

Masimo Corp(MASI)当前预期市盈率为 40.82,5 年平均预期市盈率为 35.46。

预期市盈率

合理
5 年均值 P/E
35.46
当前P/E
40.82
高估
45.39
低估
25.53

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.90
当前EV/EBITDA
21.69
高估
26.92
低估
14.89

预期市销率

合理
5 年均值 P/S
4.42
当前P/S
5.39
高估
6.43
低估
2.41

Alphio AI 对 MASI 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MASI

$166.97

情景价格

基

基准

基准 · 50%MASI

$159.11

情景价格

悲

悲观

悲观 · 25%MASI

$157.95

情景价格

持有 MASI 的大户

S

Sofinnova Investments, Inc.

+ 持有MASI

+9.67%

3个月收益率

A

Alyeska Investment Group, L.P.

+ 持有MASI

+5.05%

3个月收益率

W

Westfield Capital Management Company, L.P.

+ 持有MASI

+0.04%

3个月收益率

R

RTW Investments, LP

+ 持有MASI

-8.29%

3个月收益率

MASI 常见问题 —— 由 Alphio AI 解答

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

6 analysts cover MASI: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 188.40.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易